Investment Rating - The report maintains a "Buy" rating for the company [7] Core Views - The company plans to invest up to 3.3 billion RMB to build amino acid and supporting projects, increasing annual production capacity of threonine and MSG by 200,000 tons and 250,000 tons respectively [1][2] - The company's threonine and MSG production capacity is expected to rise from 268,000 tons and 420,000 tons in 2024 to 468,000 tons and 670,000 tons in 2027, enhancing its market share [1][2] - The report anticipates that the global threonine capacity and domestic MSG capacity will maintain a CR3 of over 80% by 2027, with the company’s market share projected to increase to 26% and 17% respectively [1][2] Summary by Sections Investment Overview - The project is located in Daqing, Heilongjiang, with a construction period of approximately 22 months and expected annual sales revenue of about 3.9 billion RMB upon reaching full capacity [2] - The company will finance the project through a mix of self-funding and bank loans, each accounting for about 50% [2] Market Conditions - The report notes that the prices for lysine and threonine have seen slight declines, but demand is expected to improve as the peak season approaches and due to the reduction in soybean meal usage [3] - The company’s corn deep processing project in Xinjiang, which includes small amino acid products, is progressing and is expected to contribute to future growth [3] Financial Projections - The report forecasts the company's net profit attributable to shareholders for 2025-2027 to be 1.32 billion, 1.41 billion, and 1.59 billion RMB respectively, representing year-on-year growth of 40%, 7%, and 12% [4] - The estimated EPS for the same period is projected to be 0.80, 0.85, and 0.96 RMB [4] - The target price is set at 9.60 RMB, with a PE ratio of 12 times for 2025, reflecting the company's early-stage project developments [4][8]